Gangliosides and Alzheimer’s Disease

  • C. G. Gottfries
Part of the Advances in Behavioral Biology book series (ABBI, volume 44)


Alzheimer’s disease (AD) was originally reserved for dementia in patients with presenile onset of symptoms. It was considered a cortical disorder with a parieto-temporallobe symptomatology (Blennow and Wallin, 1992). Since the 1960s, largely based on the histopathological observation that neurofibrillary tangles and senile plaques are found in the brains of senile dementia patients, these disorders have been named senile dementia of the Alzheimer type (SDAT) and sampled together with AD as Alzheimer-type dementia. However, in SDAT, the symptomatology is more general and/or of a subcortical type, indicating subcortical damage (Blennow and Wallin, 1992).


Caudate Nucleus Frontal White Matter Myelin Lipid Postmortem Investigation Frontal Grey Matter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Blennow, K., and Wallin, A., 1992, Clinical heterogeneity of probable Alzheimer’s disease, J. Geriatr. Psychiatry Neurol. 5: 106.PubMedGoogle Scholar
  2. Blennow, K., Davidsson, P., Wallin, A., Fredman, P., Gottfries, C.G., Manson, J.E., and Svennerholm, L., 1992, Differences in cerebrospinal fluid gangliosides between “probable Alzheimer’s disease” and normal aging, Aging 4: 301.PubMedGoogle Scholar
  3. Blennow, K., Davidsson, O., Wallin, A., Fredman, P., Gottfries, C.G., Karlsson, I., Manson, J.E., and Svennerholm, L., 1991, Gangliosides in cerebrospinal fluid in ‘probable Alzheimer’s diseisko, Arch. Neurol. 48: 1032.PubMedCrossRefGoogle Scholar
  4. Gottfries, C.G., Adolfsson, R., Aquilonius, S.M., Carlsson, A., Eckernis, S.A., Nordberg, A., Oreland, L., Svennerholm, L., Wiberg, A., and Winblad, B., 1983, Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT), Neurobiol. Aging 4: 261.PubMedCrossRefGoogle Scholar
  5. Ledeen, R.W., 1984, Biology of gangliosides: neuritogenic and neuronotrophic properties, J. Neurosci. 12: 147.Google Scholar
  6. Svennerholm, L., and Gottfries, C.G., 1993, Membrane lipids selectively diminished in Alzheimer brains suggest synapse loss as primary event in early onset form (Type I) and demyelination in late onset form (Type II), Neurochemistry,in press.Google Scholar
  7. Svennerholm, L., Gottfries, C.G., Blennow, K., Fredman, P., Karlsson, I., Manson, J.E., Toffano, G., Wallin, and A., 1990, Parenteral administration of GM1 ganglioside to presenile Alzheimer patients, Acta Neurol. Scand. 81: 48.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • C. G. Gottfries
    • 1
  1. 1.Department of Clinical NeuroscienceUniversity of GöteborgSweden

Personalised recommendations